Serum microRNA levels in patients with Crohn's disease during induction therapy by infliximab

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 6, 2014, Pages 1207-1214

  Fujioka, Shin ^a   Nakamichi, Ikuo ^a,b   Esaki, Motohiro ^a   Asano, Kouichi ^a   Matsumoto, Takayuki ^a   Kitazono, Takanari ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Crohn's disease; Infliximab; MicroRNAs

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DIPHENHYDRAMINE; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; MICRORNA; MICRORNA 125A 5P; MICRORNA 127 3P; MICRORNA 199A 3P; MICRORNA 221; MICRORNA 223; MICRORNA 224; MICRORNA 28 5P; MICRORNA 361 5P; MICRORNA 485 3P; MICRORNA 539; MICRORNA 5P28; MICRORNA LET 7D; MICRORNA LET 7E; PARACETAMOL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLON CROHN DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIET THERAPY; DISEASE MARKER; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENETIC SCREENING; HUMAN; ILEUM CROHN DISEASE; ILEUM DISEASE; MALE; MICRORNA BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK REDUCTION; RNA ANALYSIS; SINGLE DRUG DOSE; THERAPY EFFECT; WILCOXON SIGNED RANKS TEST; AGED; BLOOD; GENETICS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CROHN DISEASE; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84900560455     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12523     Document Type: Article

References (47)

1. Talley NJ, Abreu MT, Achkar JP etal. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am. J. Gastroenterol. 2011; 106: S2-S25.
2. Targan SR, Hanauer SB, van Deventer SJ etal. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 1997; 337: 1029-1035.
3. Hanauer SB, Feagan BG, Lichtenstein GR etal. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
4. Vermeire S, Louis E, Carbonez A etal. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am. J. Gastroenterol. 2002; 97: 2357-2363.
5. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharmacol. Ther. 2003; 17: 1451-1457.
6. Louis E, Vermeire S, Rutgeerts P etal. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 2002; 37: 818-824.
7. Di Sabatino A, Biancheri P, Piconese S etal. Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease. Inflamm. Bowel Dis. 2010; 16: 1891-1897.
8. Hlavaty T, Pierik M, Henckaerts L etal. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 2005; 22: 613-626.
9. Louis E, El Ghoul Z, Vermeire S etal. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 2004; 19: 511-519.
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
11. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008; 27: 5959-5974.
12. Lawrie CH, Gal S, Dunlop HM etal. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008; 141: 672-675.
13. Mitchell PS, Parkin RK, Kroh EM etal. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. U.S.A. 2008; 105: 10513-10518.
14. Chen X, Ba Y, Ma L etal. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18: 997-1006.
15. Gilad S, Meiri E, Yogev Y etal. Serum microRNAs are promising novel biomarkers. PLoS One 2008; 3: e3148.
16. Tanaka M, Oikawa K, Takanashi M etal. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009; 4: e5532.
17. Ng EK, Chong WW, Jin H etal. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-1381.
18. Ai J, Zhang R, Li Y etal. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun. 2010; 391: 73-77.
19. Murata K, Yoshitomi H, Tanida S etal. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res. Ther. 2010; 12: R86.
20. Wang G, Tam LS, Li EK etal. Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 2011; 20: 493-500.
21. Wu F, Zikusoka M, Trindade A etal. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008; 135: 1624-1635.e24.
22. Wu F, Zhang S, Dassopoulos T etal. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm. Bowel Dis. 2010; 16: 1729-1738.
23. Takagi T, Naito Y, Mizushima K etal. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. J. Gastroenterol. Hepatol. 2010; 25: S129-S133.
24. Fasseu M, Tréton X, Guichard C etal. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One 2010; 5: e13160.
25. Zahm AM, Thayu M, Hand NJ, Horner A, Leonard MB, Friedman JR. Circulating microRNA is a biomarker of pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 2011; 53: 26-33.
26. Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis. Colon Rectum 2000; 43: S85-93.
27. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008; 18: 505-516.
28. Johnson SM, Grosshans H, Shingara J etal. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647.
29. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007; 315: 1576-1579.
30. Wang S, Tang Y, Cui H etal. Let-7/miR-98 regulate Fas and Fas-mediated apoptosis. Genes Immun. 2011; 12: 149-154.
31. Geng L, Zhu B, Dai BH etal. A let-7/Fas double-negative feedback loop regulates human colon carcinoma cells sensitivity to Fas-related apoptosis. Biochem. Biophys. Res. Commun. 2011; 408: 494-499.
32. Shimizu S, Takehara T, Hikita H etal. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J. Hepatol. 2010; 52: 698-704.
33. Itoh J, de La Motte C, Strong SA, Levine AD, Fiocchi C. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 2001; 49: 35-41.
34. Ina K, Itoh J, Fukushima K etal. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J. Immunol. 1999; 163: 1081-1090.
35. Van den Brande JM, Koehler TC, Zelinkova Z etal. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 2007; 56: 509-517.
36. Di Sabatino A, Ciccocioppo R, Cinque B etal. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53: 70-77.
37. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-211.
38. Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-1157.
39. Mitoma H, Horiuchi T, Hatta N etal. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005; 128: 376-392.
40. Zwiers A, Kraal L, van de Pouw Kraan TC, Wurdinger T, Bouma G, Kraal G. Cutting edge: a variant of the IL-23R gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production. J. Immunol. 2012; 188: 1573-1577.
41. Duerr RH, Taylor KD, Brant SR etal. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463.
42. Sandborn WJ, Gasink C, Gao LL etal. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 2012; 367: 1519-1528.
43. Chen Y, Ge W, Xu L etal. miR-200b is involved in intestinal fibrosis of Crohn's disease. Int. J. Mol. Med. 2012; 29: 601-606.
44. Wu F, Guo NJ, Tian H etal. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 2011; 17: 241-250.
45. Paraskevi A, Theodoropoulos G, Papaconstantinou I, Mantzaris G, Nikiteas N, Gazouli M. Circulating microRNA in inflammatory bowel disease. J Crohns Colitis. 2012; 6: 900-904.
46. Van Limbergen J, Russell RK, Drummond HE etal. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114-1122.
47. Vernier-Massouille G, Balde M, Salleron J etal. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106-1113.